Octaplaslg (Human Plasma Protein)

Human Plasma Protein, the active ingredient in Octaplaslg, is a plasma‑derived protein concentrate presented as a liquid for intravenous use. It is employed to support hemostasis in patients with complex coagulation needs, such as those undergoing major surgery or experiencing massive hemorrhage. GNH USA supplies Octaplaslg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Octaplaslg is a plasma‑derived protein concentrate that acts on the coagulation cascade to manage bleeding disorders. - Major surgical bleeding: Provides comprehensive clotting factor replacement to control intra‑operative blood loss. - Trauma‑induced hemorrhage: Supplies essential plasma proteins to stabilize patients with massive blood loss. - Liver disease‑related coagulopathy: Helps correct deficient clotting factors in hepatic impairment. - Cardiac surgery with cardiopulmonary bypass: Supports hemostasis during and after bypass procedures.

Octaplaslg may be associated with infusion‑related reactions and immunologic events.

Common Side Effects: - Fever: Mild temperature elevation during or shortly after infusion. - Chills: Transient shaking or feeling of cold. - Headache: Mild to moderate headache post‑infusion. - Nausea: Temporary feeling of queasiness. - Mild hypotension: Slight drop in blood pressure during administration. - Rash: Localized skin redness at infusion site.

Serious or Rare Side Effects: - Anaphylaxis: Severe allergic reaction requiring immediate medical intervention. - Transfusion‑related acute lung injury (TRALI): Acute respiratory distress following infusion. - Severe hemolysis: Rapid destruction of red blood cells. - Viral transmission: Potential infection despite rigorous donor screening. - Thromboembolic events: Formation of clots in vessels. - Disseminated intravascular coagulation (DIC): Widespread clotting and bleeding.

When using Octaplaslg, clinicians should observe specific safety measures. - Verify patient identity and indication: Confirm the need for plasma‑derived protein replacement. - Assess bleeding risk: Evaluate coagulation profile before infusion. - Monitor vital signs: Observe blood pressure, heart rate, and temperature during administration. - Use aseptic technique: Prevent contamination of the infusion set. - Observe for allergic reactions: Be prepared to treat anaphylaxis if it occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octaplaslg can interact with other therapies that affect hemostasis or immune response.

Major Interactions (Avoid): - Concurrent anticoagulants (e.g., warfarin, heparin): May exacerbate bleeding risk. - High‑dose steroids: Can increase susceptibility to transfusion reactions.

Moderate Interactions (Monitor Closely): - Immunoglobulin therapy: May mask signs of transfusion‑related reactions. - Platelet inhibitors (e.g., clopidogrel): Requires careful monitoring of coagulation parameters. - Fibrinolytic agents (e.g., alteplase): Potential for altered clot stability. - Cytokine‑modulating drugs: May influence immune response to plasma proteins.